| http://www.w3.org/ns/prov#value | - Participants also agreed that there is a need for an FDA-approved medication for the treatment of severe, persistent, or recurrent dementia-related symptoms of agitation and aggression (even in the absence of psychosis) that are unresponsive to nonpharmacologic intervention.This article outlines methodological enhancements to better evaluate treatment approaches in future registration trials and p
|
